Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to "Outperform" by Oppenheimer

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) was upgraded by equities researchers at Oppenheimer from a "market perform" rating to an "outperform" rating in a note issued to investors on Tuesday, Marketbeat.com reports. The brokerage presently has a $180.00 price objective on the biotechnology company's stock. Oppenheimer's price target would suggest a potential upside of 35.69% from the company's current price.

Several other analysts have also issued reports on SRPT. Needham & Company LLC reissued a "buy" rating and set a $166.00 price target on shares of Sarepta Therapeutics in a report on Thursday, May 2nd. Mizuho raised their target price on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the stock a "buy" rating in a research note on Wednesday, February 14th. Royal Bank of Canada upped their price target on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an "outperform" rating in a research report on Thursday, February 29th. UBS Group raised their price objective on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the company a "buy" rating in a research report on Friday, March 1st. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $128.00 target price on shares of Sarepta Therapeutics in a report on Thursday, May 2nd. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, Sarepta Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $161.81.

Sarepta Therapeutics Stock Performance

SRPT stock traded up $0.96 during trading on Tuesday, reaching $132.66. The stock had a trading volume of 1,227,441 shares, compared to its average volume of 1,030,186. The stock's 50 day moving average is $125.68 and its two-hundred day moving average is $111.67. The firm has a market cap of $12.54 billion, a PE ratio of 1,197.27 and a beta of 0.95. Sarepta Therapeutics has a 52 week low of $55.25 and a 52 week high of $159.89. The company has a current ratio of 4.05, a quick ratio of 3.44 and a debt-to-equity ratio of 1.18.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.84. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The company had revenue of $413.50 million for the quarter, compared to the consensus estimate of $375.52 million. During the same quarter last year, the firm posted ($1.44) earnings per share. The firm's revenue was up 63.1% compared to the same quarter last year. As a group, equities analysts anticipate that Sarepta Therapeutics will post 2.68 earnings per share for the current year.

Insider Activity

In other Sarepta Therapeutics news, insider Bilal Arif sold 2,000 shares of the business's stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the sale, the insider now directly owns 26,836 shares of the company's stock, valued at $3,457,550.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Bilal Arif sold 2,000 shares of the stock in a transaction on Friday, March 1st. The shares were sold at an average price of $128.84, for a total value of $257,680.00. Following the sale, the insider now owns 26,836 shares of the company's stock, valued at $3,457,550.24. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Dallan Murray sold 3,635 shares of Sarepta Therapeutics stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total transaction of $508,900.00. Following the transaction, the insider now directly owns 18,125 shares of the company's stock, valued at $2,537,500. The disclosure for this sale can be found here. In the last three months, insiders have sold 25,731 shares of company stock worth $3,248,319. 7.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Sarepta Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in SRPT. Vanguard Group Inc. increased its stake in Sarepta Therapeutics by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 8,572,944 shares of the biotechnology company's stock worth $1,039,212,000 after buying an additional 41,465 shares during the period. Picton Mahoney Asset Management purchased a new position in shares of Sarepta Therapeutics during the third quarter worth approximately $2,576,000. WCM Investment Management LLC bought a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $600,000. Capula Management Ltd purchased a new stake in shares of Sarepta Therapeutics in the third quarter valued at approximately $1,409,000. Finally, State of New Jersey Common Pension Fund D grew its stake in Sarepta Therapeutics by 8.2% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 51,398 shares of the biotechnology company's stock worth $4,956,000 after purchasing an additional 3,912 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.